Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WuXi Biologics Signs LOI for $3 Billion Vaccine Manufacturing Contract

publication date: May 22, 2019

WuXi Biologics has entered into a Letter of Intent with an unnamed vaccine company to form a strategic partnership calling for WuXi Vaccines to build a dedicated manufacturing facility that will supply the partner's vaccines for global markets. WuXi Vaccines, a JV formed by WuXi Biologics and Shanghai-based Hile Bio-Technology, estimates the value of the 20-year manufacturing contract will be over $3 billion. WuXi Vaccines expects its CDMO model will enable companies to develop and manufacture vaccines globally. More details....

Stock Symbols: (HK: 2269) (SHA: 603718)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.